97627-27-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-PYRIDYL)-N'-(2,4,6-TRICHLOROPHENYL)UREA is used as a pharmaceutical agent for the inhibition of Rho-associated protein kinase (ROCK), which plays a crucial role in various cellular processes, including cell migration, adhesion, and survival. Its inhibition can lead to potential therapeutic benefits in treating a range of diseases and conditions.
Used in Research Applications:
In research settings, N-(4-PYRIDYL)-N'-(2,4,6-TRICHLOROPHENYL)UREA serves as a valuable tool for studying the role of ROCK in various biological pathways and mechanisms. By selectively inhibiting ROCK, researchers can gain insights into its function and potential as a therapeutic target for different diseases.
Used in Drug Development:
N-(4-PYRIDYL)-N'-(2,4,6-TRICHLOROPHENYL)UREA is utilized in drug development as a lead compound for the creation of new medications targeting ROCK. Its potent and selective inhibition of ROCK makes it a promising candidate for the development of drugs that can treat diseases associated with ROCK activity.

Upstream product

• 504-24-5 4-aminopyridine 
• 2505-31-9 2,4,6-trichlorophenyl isocyanate 

Relevant academic research and scientific papers

Design and synthesis of Rho kinase inhibitors (I)

Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.

NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME

An objective of the present invention is to provide compounds having Rho kinase inhibitory activity. The compounds according to the present invention are those represented by formula (I) or pharmaceutically acceptable salts or solvates thereof:Het-X-Z wherein Het represents a monocyclic or bicyclic heterocyclic group containing at least one nitrogen atom, for example, pyridyl or phthalimide; X represents group (i) -NH-C(=O)-NH-Q1-, group (ii) -NH-C(=O)-Q2-, wherein Q1 and Q2 represent a bond, alkylene, or alkenylene, or the like; and Z represents hydrogen, halogen, a monocyclic, bicyclic, or tricyclic carbocyclic group, a heterocyclic group or the like, for example, optionally substituted phenyl.

Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds

The instant invention is novel uses of known N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts thereof. Such compounds as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or N-(2,

N-phenyl-N'-pyridinylureas as anticonvulsant agents

A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.

Anticonvulsant N-(2,6-disubstituted aromatic)-n'-pyridinyl ureas

N-(2,6-Disubstitutedphenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts having anticonvulsant activity are described as well as a process for their manufacture, formulations containing the compounds and a method of trea